Company Overview and News


Add OCUL
to your dashboard

Headline News

Applied Genetic Technologies Corp.: A Forgotten Net-Net With Clear Upside Catalysts

2017-11-10 seekingalpha
AGTC has been continuing to advance its orphan drug candidates through its proprietary gene platform with XLRS the furthest along. (126-1)

Ocular Therapeutix's (OCUL) CEO Antony Mattessich on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeutix Q3 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (40-0)

Ocular Therapeutix Inc to Host Earnings Call

2017-11-07 accesswire
(37-0)

Technical Research on Waste Management Equities -- Waste Management, Covanta, Darling Ingredients, and Republic Services

2017-09-29 prnewswire
If you want a Stock Review on WM, CVA, DAR, or RSG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com is currently reviewing the following stocks: Waste Management Inc. (NYSE: WM), Covanta Holding Corp. (NYSE: CVA), Darling Ingredients Inc. (NYSE: DAR), and Republic Services Inc. (NYSE: RSG). A functioning, advanced, and efficient Waste Management sector is highly relevant to the resolution of many environment, climate, resource, and healthcare-related challenges, and has positive economic and social impacts. (281-3)

Stock Performance Review on Biotech Industry -- Vertex Pharma, Axovant Sciences, Cerecor, and Ocular Therapeutix

2017-09-28 prnewswire
If you want a Stock Review on VRTX, AXON, CERC, or OCUL then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, the NASDAQ Composite ended the day at 6,453.26, up 1.15%; the Dow Jones Industrial Average edged 0.25% higher, to finish at 22,340.71; and the S&P 500 closed at 2,507.04, marginally gaining 0.41%. Gains were broad based as six out of nine sectors finished the trading session in green. (317-1)

BRIEF-Ocular Therapeutix appoints Donald Notman as chief financial officer

2017-09-25 reuters
* Ocular Therapeutix Inc - ‍Notman will replace interim CFO George Migausky​ Source text for Eikon: Further company coverage: (37-0)

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 – OCUL

2017-08-18 accesswire
NEW YORK, NY / ACCESSWIRE / August 18, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: (0-1)

INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017

2017-08-18 accesswire
NEW YORK, NY / ACCESSWIRE / August 18, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) and certain of its officers, on behalf of shareholders who purchased Ocular securities between March 10, 2016 and July 11, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.

Biotech Stocks on Investors' Radar -- Ocular Therapeutix, Omeros, OvaScience, and Regulus Therapeutics

2017-08-18 prnewswire
If you want a Stock Review on OCUL, OMER, OVAS, or RGLS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, August 17, 2017, US markets saw broad based losses with nine out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,221.

APPROACHING DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm

2017-08-18 accesswire
IRVINE, CA / ACCESSWIRE / August 17, 2017 / Khang & Khang LLP (the ''Firm'') announces a securities class action lawsuit against Ocular Therapeutix, Inc. (''Ocular'' or the ''Company'') (NASDAQ: OCUL). Investors who purchased or otherwise acquired shares from May 5, 2017 through July 6, 2017, inclusive (the ''Class Period''), are encouraged to contact the Firm before the September 5, 2017 lead plaintiff motion deadline.

SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm

2017-08-16 accesswire
LOS ANGELES, CA / ACCESSWIRE / August 16, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Ocular shares during the Class Period should contact the firm in advance of the September 5, 2017 lead plaintiff motion deadline.

INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline - September 5, 2017

2017-08-16 accesswire
NEW YORK, NY / ACCESSWIRE / August 16, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) and certain of its officers, on behalf of shareholders who purchased Ocular securities between March 10, 2016 and July 11, 2017, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL

2017-08-16 accesswire
NEW YORK, NY / ACCESSWIRE / August 15, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 17-cv-05095, is on behalf of a class consisting of investors who purchased or otherwise acquired Ocular securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.

EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Reminds Investors with Losses to Contact the Firm

2017-08-15 accesswire
IRVINE, CA / ACCESSWIRE / August 15, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL). Investors, who purchased or otherwise acquired shares from May 5, 2017 through July 6, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the September 5, 2017 lead plaintiff motion deadline.

Stock Research Report

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its bioresorbable hydrogel-based drug product candidates are designed to provide extended delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. Its intracanalicular inserts combine its hydrogel technology with U.S. Food and Drug Administration, or FDA, approved therapeutic agents with the goal of providing extended delivery of drug to the eye. Ocular also has...

Click for full article
CUSIP: 67576A100